Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HQY
stocks logo

HQY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q4
FY2027Q1
FY2027Q2
331.89M
+6.44%
0.901
+30.64%
351.76M
+6.32%
1.129
+16.35%
347.19M
+6.56%
1.159
+7.28%
Estimates Revision
The market is revising Upward the revenue expectations for HealthEquity, Inc. (HQY) for FY2026, with the revenue forecasts being adjusted by 0.04% over the past three months. During the same period, the stock price has changed by -2.08%.
Revenue Estimates for FY2026
Revise Upward
up Image
+0.04%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+0.45%
In Past 3 Month
Stock Price
Go Down
down Image
-2.08%
In Past 3 Month
Wall Street analysts forecast HQY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQY is 121.09 USD with a low forecast of 100.00 USD and a high forecast of 134.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast HQY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQY is 121.09 USD with a low forecast of 100.00 USD and a high forecast of 134.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 95.670
sliders
Low
100.00
Averages
121.09
High
134.00
Current: 95.670
sliders
Low
100.00
Averages
121.09
High
134.00
Citizens JMP
Outperform
maintain
$117 -> $122
2025-12-04
New
Reason
Citizens JMP
Price Target
$117 -> $122
2025-12-04
New
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on HealthEquity to $122 from $117 and keeps an Outperform rating on the shares. HealthEquity appears well-positioned to benefit from HSA market expansion, accretion from a favorable member rate mix, and HSA repricing, while continued investment in its technologies and platform is also expected to strengthen the company's competitive advantage, the analyst tells investors in a research note.
BMO Capital
Sean Dodge
Market Perform
initiated
$100
2025-11-12
Reason
BMO Capital
Sean Dodge
Price Target
$100
2025-11-12
initiated
Market Perform
Reason
BMO Capital analyst Sean Dodge initiated coverage of HealthEquity with a Market Perform rating and $100 price target. The firm is positive on the backdrop for health savings account account growth but views the shares as fully valued heading into a lower rate environment.
JPMorgan
Alexei Gogolev
Overweight
maintain
$125 -> $126
2025-09-03
Reason
JPMorgan
Alexei Gogolev
Price Target
$125 -> $126
2025-09-03
maintain
Overweight
Reason
JPMorgan analyst Alexei Gogolev raised the firm's price target on HealthEquity to $126 from $125 and keeps an Overweight rating on the shares. The company reported solid Q2 results despite labor market weakness, the analyst tells investors in a research note.
RBC Capital
Outperform
maintain
$109 -> $110
2025-09-03
Reason
RBC Capital
Price Target
$109 -> $110
2025-09-03
maintain
Outperform
Reason
RBC Capital raised the firm's price target on HealthEquity to $110 from $109 and keeps an Outperform rating on the shares. The company delivered a strong beat and raise, largely due to improvements in gross margin, and the firm sees tailwinds for the company as it both de-risks its HSA cash portfolio with additional forward contracts in FY26, setting up yield improvement in FY27 and beyond, the analyst tells investors in a research note. RBC further cites HealthEquity reducing interest rate sensitivity and leveraging AI to further strengthen its Service gross margins.
Jefferies
Glen Santangelo
Buy
maintain
$130 -> $134
2025-09-03
Reason
Jefferies
Glen Santangelo
Price Target
$130 -> $134
2025-09-03
maintain
Buy
Reason
Jefferies analyst Glen Santangelo raised the firm's price target on HealthEquity to $134 from $130 and keeps a Buy rating on the shares. The firm maintains its positive view on HealthEquity and points to the company's solid Q2 and accompanying guidance raise as indications of continued strong execution by management that's translating to stock-driving earnings outperformance. The meaningful tailwind from One Big Beautiful Bill Act's expansion of HSA eligibility is a notable positive that should boost HealthEquity's go-forward revenue and earnings outlooks, Jefferies adds. Concerns about interest rate outlook are more than adequately reflected in the stock, the firm argues.
Raymond James
C. Gregory Peters
Strong Buy
maintain
$115 -> $120
2025-07-08
Reason
Raymond James
C. Gregory Peters
Price Target
$115 -> $120
2025-07-08
maintain
Strong Buy
Reason
Raymond James analyst C. Gregory Peters raised the firm's price target on HealthEquity to $120 from $115 and keeps a Strong Buy rating on the shares. HealthEquity's management made considerable progress in Q1 on addressing the fraud activity that plagued the company in the last three quarters, the analyst tells investors in a research note. The firm expects HealthEquity to deliver double digit free cash flow and earnings growth with additional margin expansion through fiscal 2028.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Healthequity Inc (HQY.O) is 24.06, compared to its 5-year average forward P/E of 35.40. For a more detailed relative valuation and DCF analysis to assess Healthequity Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
35.40
Current PE
24.06
Overvalued PE
47.48
Undervalued PE
23.32

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
19.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
23.82
Undervalued EV/EBITDA
14.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.20
Current PS
0.00
Overvalued PS
7.21
Undervalued PS
5.18
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 213.73% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

HQY News & Events

Events Timeline

(ET)
2025-12-03
16:20:00
HealthEquity Reports Q3 Revenue of $322.16M with Net Income of $52M
select
2025-12-03
16:20:00
Company Raises FY26 Revenue Outlook to $1.3B
select
2025-11-13 (ET)
2025-11-13
09:16:00
HealthEquity to Improve Member Experience Using Agentic AI
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
12-04NASDAQ.COM
PinnedHealthEquity Reports Significant Q3 Net Income Increase; Anticipates 8.5% to 9.3% Revenue Growth for the Year

  • Strong Financial Performance: HealthEquity, Inc. reported a significant increase in Q3 FY26 earnings, with GAAP net income rising to $51.7 million and total revenue reaching $322.2 million, a 7% increase from the previous year.

  • Growth in HSA Accounts: The company saw a 6% increase in Health Savings Accounts (HSAs) to 10.1 million and a 15% rise in HSA assets to $34.4 billion, reflecting strong account expansion.

  • Future Revenue Projections: For the fiscal year ending January 31, 2026, HealthEquity anticipates revenue between $1.302 to $1.312 billion and GAAP net income forecasted between $197 million to $205 million.

  • Stock Performance: HealthEquity's stock closed at $98.46, with a trading volume of approximately 1.4 million shares, indicating active market interest despite a slight decline of 0.24%.

[object Object]
Preview
9.5
12-04NASDAQ.COM
PinnedHealthEquity, Inc. Reports Q3 Profit Growth Exceeding Expectations

  • Earnings Performance: HealthEquity, Inc. reported a third-quarter profit of $51.69 million, or $0.59 per share, significantly up from $5.70 million, or $0.06 per share, in the same period last year, exceeding analysts' expectations.

  • Adjusted Earnings: The company’s adjusted earnings for the quarter were $87.67 million, or $1.01 per share, surpassing the average analyst estimate of $0.91 per share.

  • Revenue Growth: Revenue increased by 7.2% to $322.16 million compared to $300.43 million in the previous year.

  • Future Guidance: HealthEquity provided full-year EPS guidance of $3.87 - $3.95 and revenue guidance of $1.302 - $1.312 billion.

[object Object]
Preview
2.0
05:00 AMNASDAQ.COM
HealthEquity Falls Below 200-Day Moving Average - Significant Development for HQY
  • 52 Week Range: HQY's stock has a 52-week low of $74.07 and a high of $116.65, with the last trade recorded at $95.67.
  • Market Analysis: The article mentions other stocks that have recently fallen below their 200-day moving average.
  • Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
  • Stock Performance Insight: The information provided offers insights into HQY's stock performance within the broader market context.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Healthequity Inc (HQY) stock price today?

The current price of HQY is 95.67 USD — it has decreased -3.01 % in the last trading day.

arrow icon

What is Healthequity Inc (HQY)'s business?

HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking.

arrow icon

What is the price predicton of HQY Stock?

Wall Street analysts forecast HQY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQY is 121.09 USD with a low forecast of 100.00 USD and a high forecast of 134.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Healthequity Inc (HQY)'s revenue for the last quarter?

Healthequity Inc revenue for the last quarter amounts to 322.16M USD, increased 7.23 % YoY.

arrow icon

What is Healthequity Inc (HQY)'s earnings per share (EPS) for the last quarter?

Healthequity Inc. EPS for the last quarter amounts to 0.59 USD, increased 883.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Healthequity Inc (HQY)'s fundamentals?

The market is revising Upward the revenue expectations for HealthEquity, Inc. (HQY) for FY2026, with the revenue forecasts being adjusted by 0.04% over the past three months. During the same period, the stock price has changed by -2.08%.
arrow icon

How many employees does Healthequity Inc (HQY). have?

Healthequity Inc (HQY) has 3105 emplpoyees as of December 05 2025.

arrow icon

What is Healthequity Inc (HQY) market cap?

Today HQY has the market capitalization of 8.24B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free